Cargando…

Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis

OBJECTIVES: Cardiovascular (CV) morbidity and mortality, and perpetuated synovial angiogenesis have been associated with RA. In our study we evaluated angiogenic factors in relation to vascular inflammation and function, and clinical markers in RA patients undergoing 1-year tofacitinib therapy. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerekes, György, Czókolyová, Monika, Hamar, Attila, Pusztai, Anita, Tajti, Gábor, Katkó, Mónika, Végh, Edit, Pethő, Zsófia, Bodnár, Nóra, Horváth, Ágnes, Soós, Boglárka, Szamosi, Szilvia, Hascsi, Zsolt, Harangi, Mariann, Hodosi, Katalin, Panyi, György, Seres, Tamás, Szűcs, Gabriella, Szekanecz, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593522/
https://www.ncbi.nlm.nih.gov/pubmed/37871914
http://dx.doi.org/10.1093/rheumatology/kead502
_version_ 1785124459244421120
author Kerekes, György
Czókolyová, Monika
Hamar, Attila
Pusztai, Anita
Tajti, Gábor
Katkó, Mónika
Végh, Edit
Pethő, Zsófia
Bodnár, Nóra
Horváth, Ágnes
Soós, Boglárka
Szamosi, Szilvia
Hascsi, Zsolt
Harangi, Mariann
Hodosi, Katalin
Panyi, György
Seres, Tamás
Szűcs, Gabriella
Szekanecz, Zoltán
author_facet Kerekes, György
Czókolyová, Monika
Hamar, Attila
Pusztai, Anita
Tajti, Gábor
Katkó, Mónika
Végh, Edit
Pethő, Zsófia
Bodnár, Nóra
Horváth, Ágnes
Soós, Boglárka
Szamosi, Szilvia
Hascsi, Zsolt
Harangi, Mariann
Hodosi, Katalin
Panyi, György
Seres, Tamás
Szűcs, Gabriella
Szekanecz, Zoltán
author_sort Kerekes, György
collection PubMed
description OBJECTIVES: Cardiovascular (CV) morbidity and mortality, and perpetuated synovial angiogenesis have been associated with RA. In our study we evaluated angiogenic factors in relation to vascular inflammation and function, and clinical markers in RA patients undergoing 1-year tofacitinib therapy. METHODS: Thirty RA patients treated with either 5 mg or 10 mg twice daily tofacitinib were included in a 12-month follow-up study. Eventually, 26 patients completed the study and were included in data analysis. Levels of various angiogenic cytokines (TNF-α, IL-6), growth factors [VEGF, basic fibroblast (bFGF), epidermal (EGF), placental (PlGF)], cathepsin K (CathK), CXC chemokine ligand 8 (CXCL8), galectin-3 (Gal-3) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) were determined at baseline, and at 6 and 12 months after initiating tofacitinib treatment. In order to assess flow-mediated vasodilation, common carotid intima-media thickness (ccIMT) and carotid-femoral pulse-wave velocity, ultrasonography was performed. Synovial and aortic inflammation was also assessed by (18)F-fluorodeoxyglucose-PET/CT. RESULTS: One-year tofacitinib therapy significantly decreased IL-6, VEGF, bFGF, EGF, PlGF and CathK, while it increased Gal-3 production (P < 0.05). bFGF, PlGF and NT-proBNP levels were higher, while platelet-endothelial cell adhesion molecule 1 (PECAM-1) levels were lower in RF-seropositive patients (P < 0.05). TNF-α, bFGF and PlGF correlated with post-treatment synovial inflammation, while aortic inflammation was rather dependent on IL-6 and PECAM-1 as determined by PET/CT (P < 0.05). In the correlation analyses, NT-proBNP, CXCL8 and Cath variables correlated with ccIMT (P < 0.05). CONCLUSIONS: Decreasing production of bFGF, PlGF or IL-6 by 1-year tofacitinib therapy potentially inhibits synovial and aortic inflammation. Although NT-proBNP, CXCL8 and CathK were associated with ccIMT, their role in RA-associated atherosclerosis needs to be further evaluated.
format Online
Article
Text
id pubmed-10593522
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105935222023-10-24 Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis Kerekes, György Czókolyová, Monika Hamar, Attila Pusztai, Anita Tajti, Gábor Katkó, Mónika Végh, Edit Pethő, Zsófia Bodnár, Nóra Horváth, Ágnes Soós, Boglárka Szamosi, Szilvia Hascsi, Zsolt Harangi, Mariann Hodosi, Katalin Panyi, György Seres, Tamás Szűcs, Gabriella Szekanecz, Zoltán Rheumatology (Oxford) Clinical Science OBJECTIVES: Cardiovascular (CV) morbidity and mortality, and perpetuated synovial angiogenesis have been associated with RA. In our study we evaluated angiogenic factors in relation to vascular inflammation and function, and clinical markers in RA patients undergoing 1-year tofacitinib therapy. METHODS: Thirty RA patients treated with either 5 mg or 10 mg twice daily tofacitinib were included in a 12-month follow-up study. Eventually, 26 patients completed the study and were included in data analysis. Levels of various angiogenic cytokines (TNF-α, IL-6), growth factors [VEGF, basic fibroblast (bFGF), epidermal (EGF), placental (PlGF)], cathepsin K (CathK), CXC chemokine ligand 8 (CXCL8), galectin-3 (Gal-3) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) were determined at baseline, and at 6 and 12 months after initiating tofacitinib treatment. In order to assess flow-mediated vasodilation, common carotid intima-media thickness (ccIMT) and carotid-femoral pulse-wave velocity, ultrasonography was performed. Synovial and aortic inflammation was also assessed by (18)F-fluorodeoxyglucose-PET/CT. RESULTS: One-year tofacitinib therapy significantly decreased IL-6, VEGF, bFGF, EGF, PlGF and CathK, while it increased Gal-3 production (P < 0.05). bFGF, PlGF and NT-proBNP levels were higher, while platelet-endothelial cell adhesion molecule 1 (PECAM-1) levels were lower in RF-seropositive patients (P < 0.05). TNF-α, bFGF and PlGF correlated with post-treatment synovial inflammation, while aortic inflammation was rather dependent on IL-6 and PECAM-1 as determined by PET/CT (P < 0.05). In the correlation analyses, NT-proBNP, CXCL8 and Cath variables correlated with ccIMT (P < 0.05). CONCLUSIONS: Decreasing production of bFGF, PlGF or IL-6 by 1-year tofacitinib therapy potentially inhibits synovial and aortic inflammation. Although NT-proBNP, CXCL8 and CathK were associated with ccIMT, their role in RA-associated atherosclerosis needs to be further evaluated. Oxford University Press 2023-10-23 /pmc/articles/PMC10593522/ /pubmed/37871914 http://dx.doi.org/10.1093/rheumatology/kead502 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Science
Kerekes, György
Czókolyová, Monika
Hamar, Attila
Pusztai, Anita
Tajti, Gábor
Katkó, Mónika
Végh, Edit
Pethő, Zsófia
Bodnár, Nóra
Horváth, Ágnes
Soós, Boglárka
Szamosi, Szilvia
Hascsi, Zsolt
Harangi, Mariann
Hodosi, Katalin
Panyi, György
Seres, Tamás
Szűcs, Gabriella
Szekanecz, Zoltán
Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis
title Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis
title_full Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis
title_fullStr Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis
title_full_unstemmed Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis
title_short Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis
title_sort effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593522/
https://www.ncbi.nlm.nih.gov/pubmed/37871914
http://dx.doi.org/10.1093/rheumatology/kead502
work_keys_str_mv AT kerekesgyorgy effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT czokolyovamonika effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT hamarattila effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT pusztaianita effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT tajtigabor effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT katkomonika effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT veghedit effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT pethozsofia effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT bodnarnora effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT horvathagnes effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT soosboglarka effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT szamosiszilvia effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT hascsizsolt effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT harangimariann effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT hodosikatalin effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT panyigyorgy effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT serestamas effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT szucsgabriella effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis
AT szekaneczzoltan effectsof1yeartofacitinibtherapyonangiogenicbiomarkersinrheumatoidarthritis